Oculis, a clinical-stage biotechnology company focused on the development of non-invasive topical treatment for back-of-the-eye diseases, announced the completion of a CHF 20m Series B financing. The round involved a syndicate of leading transatlantic life sciences investors composed of Novartis Venture Fund, Pivotal bioVenture Partners and Bay City Capital as well as existing investors including Brunnur Ventures and Silfurberg.

In connection with this financing, Oculis is relocating its corporate headquarters to Lausanne, Switzerland, while keeping its R&D activities in Reykjavik, Iceland.

Vischer acted as counsel to the new investors with respect to the financing and assisted Oculis with its relocation to Switzerland. The team was led by Dr. Matthias Staehelin (Partner, Corporate) and Nadia Tarolli (Partner, Tax) with the support of Vincent S. Reardon (Senior Associate, Corporate), Luzius Zumstein (Associate, Corporate) and Adrian Briner (Associate, Tax).